NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats

Neuropeptides. 2007 Aug;41(4):239-47. doi: 10.1016/j.npep.2007.03.001. Epub 2007 May 23.

Abstract

The present study used the endpoint of hypothermia to investigate cannabinoid and nociceptin/orphanin FQ (N/OFQ) interactions in conscious animals. Prior work has established that cannabinoids produce hypothermia by activating central cannabinoid CB(1) receptors. The administration of N/OFQ into the brain also causes significant hypothermia. Those data suggest a link between cannabinoid CB(1) receptors and N/OFQ peptide (NOP) receptors in the production of hypothermia. Therefore, we determined if NOP receptor activation is required for cannabinoid-evoked hypothermia and if cannabinoid CB(1) receptor activation is necessary for N/OFQ-induced hypothermia. In actual experiments, a cannabinoid agonist, WIN 55212-2 (2.5, 5, and 10 mg/kg, i.p.), caused significant hypothermia in male Sprague-Dawley rats (200-225 g). A NOP receptor antagonist, JTC-801 (1 mg/kg, i.p.), did not affect body temperature. For combined administration, JTC-801 (1 mg/kg, i.p.) blocked a significant proportion of the hypothermia caused by each dose of WIN 55212-2 (2.5, 5, and 10 mg/kg, i.p.). JTC-801 (1 mg/kg, i.p.) also blocked the hypothermia caused by another cannabinoid agonist, CP-55, 940 (1 mg/kg, i.p.). In separate experiments, the direct administration of N/OFQ (9 microg/rat, i.c.v.) into the brain produced significant hypothermia. The hypothermic effect of N/OFQ was blocked by JTC-801 (1 mg/kg, i.p.) but not by a selective cannabinoid CB(1) antagonist, SR 141716A (5 mg/kg, i.m.). The finding that a NOP receptor antagonist abolishes a significant percentage of cannabinoid-induced hypothermia suggests that NOP receptor activation is required for cannabinoids to produce hypothermia. This interaction, quantitated in the present study, is the first evidence that NOP receptors mediate a cannabinoid-induced effect in conscious animals.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aminoquinolines / metabolism*
  • Analgesics / metabolism
  • Animals
  • Benzamides / metabolism*
  • Benzoxazines / metabolism
  • Body Temperature
  • Cannabinoids / agonists
  • Cannabinoids / antagonists & inhibitors
  • Cannabinoids / pharmacology*
  • Humans
  • Hypothermia / chemically induced*
  • Male
  • Morpholines / metabolism
  • Naphthalenes / metabolism
  • Narcotic Antagonists
  • Nociceptin Receptor
  • Piperidines / metabolism
  • Pyrazoles / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Receptor, Cannabinoid, CB1 / metabolism
  • Receptors, Opioid* / metabolism
  • Rimonabant

Substances

  • Aminoquinolines
  • Analgesics
  • Benzamides
  • Benzoxazines
  • Cannabinoids
  • Morpholines
  • N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide
  • Naphthalenes
  • Narcotic Antagonists
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Receptors, Opioid
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Rimonabant
  • Nociceptin Receptor